Skip to main content

Digital Trends may earn a commission when you buy through links on our site. Why trust us?

Gene therapy helps people with monochrome vision to see in color

Color blindness is usually a hereditary condition. While there have been a few high-tech methods, such as special glasses, to help people deal with it, to date there hasn’t been much in the way of a permanent solution to the problem. Perhaps until now, that is.

An initial trial in patients suggests that a new gene therapy treatment for helping overcome color blindness, developed by researchers in Germany, is completely safe. The researchers also obtained evidence that the treatment works.

The condition in question, referred to as achromatopsia, is one of the rarer types of color blindness. Approximately 8% of men and 0.5% of women have some kind of color blindness which renders them unable to see certain colors (red-green color blindness being the most common). Achromatopsia, however, affects just 1 out of 33,000 people — which nonetheless adds up to a sizable cohort of people worldwide. The condition is due to non-functioning or absent retinal cones, and it makes the world appear entirely black and white. It also causes blurred vision and makes eyes extremely sensitive to bright light.

In around one-third of patients with achromatopsia, the condition is caused by a gene called CNGA3. The new treatment, developed by researchers at the Institute for Ophthalmic Research at the University Hospitals in Tübingen and Departments of Pharmacy and Ophthalmology at Ludwig Maximilian University of Munich, makes it possible to inject a corrected version of the gene into a patient’s retina using a harmless virus.

A trial involving nine achromatopsia patients, aged between 24 and 59, was recently carried out at the University Eye Hospital Tübingen. There were no health issues, and the retina suffered no permanent change or damage as a result of the procedure. Patients involved in the study saw their vision improve in terms of focus, contrast perception, and — most crucially — color vision.

“The study is an important first step,” Martin Biel from the Department of Pharmacy at LMU, said in a statement. “It represents a milestone on the road to a curative therapy of achromatopsia, and we expect even better treatment success in the future.”

A paper describing the research was recently published in the journal JAMA Ophthalmology 2020.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Elon Musk’s Neuralink now recruiting for first human trials
Everything you need to know about Neuralink

Elon Musk’s Neuralink company has announced that it’s now accepting applications from human subjects willing to have its experimental N1 computer interface implanted in their brain.

Neuralink’s first in-human study, called PRIME (Precise Robotically Implanted Brain-Computer Interface), is encouraging interest from those with quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS). They should also be at least 22 years old and have a consistent and reliable caregiver.

Read more
Amazon is hiring a quarter of a million extra workers for the holiday season
A warehouse worker at Amazon.

Eyeing the upcoming holiday rush, Amazon announced on Tuesday that it’s seeking to hire 250,000 warehouse and delivery workers to work alongside its existing team. A bump in the hourly pay rate is also being offered in the hope of encouraging more people to sign up.

The e-commerce giant usually runs hiring campaigns around this time of year to help it manage the huge volume of extra deliveries that come its way as folks jump online to buy gifts and other items during the holiday season.

Read more
NASA’s Artemis moon astronauts suit up for mission practice run
NASA's crew for the Artemis II lunar mission.

The four Artemis II astronauts who will embark on a flyby of the moon in November next year successfully conducted a pre-launch practice run on Wednesday.

In line with launch day procedures, NASA astronauts Christina Koch, Victor Glover, and Reid Wiseman, along with Canadian Space Agency astronaut Jeremy Hansen, started the day by waking up inside the crew quarters at the Neil Armstrong Operations and Checkout Building at the Kennedy Space Center in Florida.

Read more